As reported by the National Health Executive, patients in the UK could gain earlier access to cutting-edge medical technologies as the number of approved clinical investigations reaches its highest level on record
New data from the Medicines and Healthcare products Regulatory Agency (MHRA) shows a 17% increase in approved clinical investigations compared with the previous year, with more companies choosing Great Britain as a base to test advanced medical devices.
Regulators say the UK’s approval system is helping drive the growth. Since September 2023, the MHRA has met 100% of its statutory deadlines for investigation decisions. In 2025, the average time taken to approve studies fell to 51 days – nine days quicker than the 60-day target. The agency also offers direct scientific guidance to developers to help strengthen study design and improve patient safety.
Artificial intelligence-powered technologies are among the fastest-growing areas of research. Newly approved investigations include imaging systems designed to detect disease earlier and support clinical decision-making, a digital app that adjusts COPD treatment in real time while providing clinicians with enhanced patient data, and emerging innovations aimed at protecting and restoring sight.
Officials say the rise in clinical trials could give patients access to potentially life-changing treatments sooner. For the NHS, the expansion offers new diagnostic tools, more precise therapies and improved management of long-term conditions.
The increase follows a series of measures introduced by the MHRA to encourage innovation and make it easier for smaller companies to bring forward new technologies.
